Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 10;11(11):CD011932.
doi: 10.1002/14651858.CD011932.pub2.

Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants

Maria Pierro  1 , Bernard Thébaud, Roger Soll
Affiliations

Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants

Maria Pierro et al. Cochrane Database Syst Rev. .

Abstract

Background: Bronchopulmonary dysplasia (BPD) remains a major complication of prematurity and currently lacks efficient treatments. Mesenchymal stem/stromal cells (MSCs) have been extensively explored as a potential therapy in several preclinical and clinical settings. Human and animal MSCs have been shown to prevent and treat lung injury in various preclinical models of lung diseases, including experimental BPD.

Objectives: To determine if MSCs, administered intravenously or endotracheally, are safe and effective in preventing or treating BPD, or both, in preterm infants.

Search methods: We used the standard search strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 10), MEDLINE via PubMed (1966 to 6 November 2016), Embase (1980 to 6 November 2016), and CINAHL (1982 to 6 November 2016). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomized controlled trials (RCTs) and quasi-RCTs.

Selection criteria: We considered RCTs and quasi-RCTs investigating prevention or treatment of BPD, or both, in preterm infants.

Data collection and analysis: Two review authors independently assessed trial quality according to prespecified criteria.

Main results: We found no RCTs or quasi-RCTs addressing the use of MSCs for prevention or treatment of BPD in premature infants. Two RCTs are currently registered and ongoing.

Authors' conclusions: There is insufficient evidence to determine the safety and efficacy of MSCs in the treatment or prevention of BPD in premature infants. The results of the ongoing trials addressing this issue are expected in the near future.

PubMed Disclaimer

Conflict of interest statement

Maria Pierro is a funded researcher in the field of mesenchymal stem cells.

Bernard Thébaud's work on mesenchymal stem cells is supported by the Canadian Institute for Health Research, the Canadian Stem Cell Network, the Canadian Thoracic Society, the Ottawa Hospital Research Institute and the Children's Hospital of Eastern Ontario Research Institute, and the Ontario Institute of Regenerative Medicine.

Roger Soll is the Co‐ordinating Editor of the Cochrane Neonatal Review Group, but played no part in determining if this review was acceptable for publication.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011932

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

Chang 2014 {published data only}
    1. Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose‐escalation clinical trial. Journal of Pediatrics 2014;164(5):966‐72.e6. [DOI: 10.1016/j.jpeds.2013.12.011; PUBMED: 24508444] - DOI - PubMed
Rudnicki 2015 {published data only}
    1. Rudnicki J, Kawa MP, Kotowski M, Michalczyk B, Ustianowski P, Czajka R, et al. Clinical evaluation of the safety and feasibility of whole autologous cord blood transplant as a source of stem and progenitor cells for extremely premature neonates: preliminary report. Experimental and Clinical Transplantation 2015;13(6):563‐72. [DOI: 10.6002/ect.2015.0081; PUBMED: 26643677] - DOI - PubMed

References to ongoing studies

NCT01207869 {published data only}
    1. NCT01207869. Intratracheal umbilical cord‐derived mesenchymal stem cells for severe bronchopulmonary dysplasia [Intratracheal instillation of umbilical cord‐derived mesenchymal stem cells as a rescue treatment for severe bronchopulmonary dysplasia]. clinicaltrials.gov/show/NCT01207869 (first received 11 September 2010).
NCT01284673 {published data only}
    1. NCT01284673. Characterization of the cord blood stem cell in situation of neonatal asphyxia. clinicaltrials.gov/show/NCT01284673 (first received 16 April 2010).
NCT01632475 {published data only}
    1. NCT01632475. Follow‐up study of safety and efficacy of Pneumostem in premature infants with bronchopulmonary dysplasia [Long term follow‐up study of the safety and exploratory efficacy of Pneumostem in premature infants with bronchopulmonary dysplasia]. clinicaltrials.gov/show/NCT01632475 (first received 27 June 2012).
NCT01828957 {published data only}
    1. NCT01828957. Efficacy and safety evaluation of Pneumostem versus a control group for treatment of BPD in premature infants [Randomized, double‐blind, multi‐center, phase II clinical trial to evaluate the efficacy and safety of Pneumostem versus a control group for treatment of bronchopulmonary dysplasia in premature infants]. clinicaltrials.gov/show/NCT01828957 (first received 2 April 2013).
NCT01897987 {published data only}
    1. NCT01897987. Follow‐up safety and efficacy evaluation on subjects who completed PNEUMOSTEM phase‐II clinical trial [Follow‐up safety and efficacy evaluation on subjects who completed the initial stage of PNEUMOSTEM phase‐II clinical trial]. clinicaltrials.gov/show/NCT01897987 (first received 4 July 2013).
NCT02023788 {published data only}
    1. NCT02023788. Long‐term safety and efficacy follow‐up study of PNEUMOSTEM in patients who completed PNEUMOSTEM phase‐I study. clinicaltrials.gov/show/NCT02023788 (first received 17 December 2013).
NCT02274428 {published data only}
    1. NCT02274428. Phase 1 clinical trial of PNEUMOSTEM treatment in premature infants with intraventricular hemorrhage. clinicaltrials.gov/show/NCT02274428 (first received 2 October 2014).
NCT02381366 {published data only}
    1. NCT02381366. Safety and efficacy of PNEUMOSTEM in premature infants at high risk for bronchopulmonary dysplasia (BPD) ‐ a US study [A phase I/II, open‐label dose escalation trial to evaluate the safety and efficacy of two dose levels of PNEUMOSTEM in premature infants at high risk for bronchopulmonary dysplasia (BPD)]. clinicaltrials.gov/show/NCT02381366 (first received 15 February 2015).
NCT02443961 {published data only}
    1. NCT02443961. Mesenchymal stem cell therapy for bronchopulmonary dysplasia in preterm babies [Clinical trial: security and feasibility of mesenchymal stem cell therapy in treatment and prevention of bronchopulmonary dysplasia in preterm babies]. clinicaltrials.gov/show/NCT02443961 (first received 4 May 2015).
NCT02673788 {published data only}
    1. NCT02673788. Follow‐up study of safety and efficacy of Pneumostem in premature infants with intraventricular hemorrhage. clinicaltrials.gov/show/NCT02673788 (first received 26 January 2016).

Additional references

Ahn 2017
    1. Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two‐year follow‐up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. Journal of Pediatrics 2017;185:49–54.e2. [DOI: 10.1016/j.jpeds.2017.02.061; NCT01632475; PUBMED: 28341525] - DOI - PubMed
Alagesan 2014
    1. Alagesan S, Griffin MD. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy?. Current Opinion in Organ Transplantation 2014;19(1):65‐72. [DOI: 10.1097/MOT.0000000000000043; PUBMED: 24370985] - DOI - PubMed
Anderson 2006
    1. Anderson PJ, Doyle LW. Neurodevelopmental outcome of bronchopulmonary dysplasia. Seminars in Perinatology 2006;30(4):227‐32. [DOI: 10.1053/j.semperi.2006.05.010; PUBMED: 16860163] - DOI - PubMed
Antunes 2014
    1. Antunes MA, Laffey JG, Pelosi P, Rocco PR. Mesenchymal stem cell trials for pulmonary diseases. Journal of Cellular Biochemistry 2014;115(6):1023‐32. [DOI: 10.1002/jcb.24783; PUBMED: 24515922] - DOI - PubMed
Aslam 2009
    1. Aslam M, Baveja R, Liang OD, Fernandez‐Gonzalez A, Lee C, Mitsialis SA, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. American Journal of Respiratory and Critical Care Medicine 2009;180(11):1122‐30. [DOI: 10.1164/rccm.200902-0242OC; PUBMED: 19713447] - DOI - PMC - PubMed
Baker 2014
    1. Baker CD, Alvira CM. Disrupted lung development and bronchopulmonary dysplasia: opportunities for lung repair and regeneration. Current Opinion in Pediatrics 2014;26(3):306‐14. [DOI: 10.1097/MOP.0000000000000095; PUBMED: 24739494] - DOI - PMC - PubMed
Batsali 2013
    1. Batsali AK, Kastrinaki MC, Papadaki HA. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Current Stem Cell Research & Therapy 2013;8(2):144‐55. [PUBMED: 23279098] - PubMed
Beam 2014
    1. Beam KS, Aliaga S, Ahlfeld SK, Cohen‐Wolkowiez M, Smith PB, Laughon MM. A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. Journal of Perinatology 2014;34(9):705‐10. [DOI: 10.1038/jp.2014.126; PUBMED: 25010224] - DOI - PMC - PubMed
Bell 1978
    1. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187(1):1‐7. [PUBMED: 413500] - PMC - PubMed
Bellayr 2014
    1. Bellayr IH, Catalano JG, Lababidi S, Yang AX, Lo Surdo JL, Bauer SR, et al. Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Research & Therapy 2014;5(2):59. [DOI: 10.1186/scrt448; PUBMED: 24780490] - DOI - PMC - PubMed
Bhandari 2006
    1. Bhandari A, Panitch HB. Pulmonary outcomes in bronchopulmonary dysplasia. Seminars in Perinatology 2006;30(4):219‐26. [DOI: 10.1053/j.semperi.2006.05.009; PUBMED: 16860162] - DOI - PubMed
Blau 2001
    1. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function?. Cell 2001;105(7):829‐41. [PUBMED: 11439179] - PubMed
Chang 2009
    1. Chang YS, Oh W, Choi SJ, Sung DK, Kim SY, Choi EY, et al. Human umbilical cord blood‐derived mesenchymal stem cells attenuate hyperoxia‐induced lung injury in neonatal rats. Cell Transplant 2009;18(8):869–86. [DOI: 10.3727/096368909X471189; PUBMED: 19500472] - DOI - PubMed
Chang 2011
    1. Chang YS, Choi SJ, Sung DK, Kim SY, Oh W, Yang YS, et al. Intratracheal transplantation of human umbilical cord blood‐derived mesenchymal stem cells dose‐dependently attenuates hyperoxia‐induced lung injury in neonatal rats. Cell Transplantation 2011;20(11‐12):1843‐54. [DOI: 10.3727/096368911X565038; PUBMED: 23167961] - DOI - PubMed
da Silva Meirelles 2006
    1. Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post‐natal organs and tissues. Journal of Cell Science 2006;119(Pt 11):2204–13. [DOI: 10.1242/jcs.02932; PUBMED: 16684817] - DOI - PubMed
Darlow 2011
    1. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birthweight infants. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD000501.pub3] - DOI - PubMed
Dmitrieva 2012
    1. Dmitrieva RI, Minullina IR, Bilibina AA, Tarasova OV, Anisimov SV, Zaritskey AY. Bone marrow‐ and subcutaneous adipose tissue‐derived mesenchymal stem cells: differences and similarities. Cell Cycle 2012;11(2):377–83. [DOI: 10.4161/cc.11.2.18858; PUBMED: 22189711] - DOI - PubMed
Dominici 2006
    1. Dominici M, Blanc K, Mueller I, Slaper‐Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):315‐7. [DOI: 10.1080/14653240600855905; PUBMED: 16923606] - DOI - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. [PUBMED: 9310563] - PMC - PubMed
Ehrenkranz 2005
    1. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116(6):1353‐60. [DOI: 10.1542/peds.2005-0249; PUBMED: 16322158] - DOI - PubMed
Farstad 2011
    1. Farstad T, Bratlid D, Medbo S, Markestad T, Norwegian Extreme Prematurity Study Group. Bronchopulmonary dysplasia ‐ prevalence, severity and predictive factors in a national cohort of extremely premature infants. Acta Paediatrica 2011;100(1):53‐8. [DOI: 10.1111/j.1651-2227.2010.01959.x; PUBMED: 20653607] - DOI - PubMed
FDA 2011
    1. U.S. Department of Health and Human Services, Food, Drug Administration. Center for Biologics Evaluation and Research. Guidance for industry: current good tissue practice (CGTP) and additional requirements for manufacturers of human cells, tissues, and cellular and tissue‐based products (HCT/Ps). www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulator... 2011 (accessed prior to 23 October 2017).
Galipeau 2015
    1. Galipeau J, Krampera M. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy 2015;17(2):125‐7. [DOI: 10.1016/j.jcyt.2014.12.008; PUBMED: 25593076] - DOI - PubMed
Gebler 2012
    1. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine 2012;18(2):128‐34. [DOI: 10.1016/j.molmed.2011.10.004; PUBMED: 22118960] - DOI - PubMed
GRADEpro GDT [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version (accessed 5 July 2017). Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Higgins 2011
    1. Higgins A, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
ICCROP 2005
    1. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Archives of Ophthalmology 2005;123(7):991‐9. [DOI: 10.1001/archopht.123.7.991; PUBMED: 16009843] - DOI - PubMed
Ikebe 2014
    1. Ikebe C, Suzuki K. Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. BioMed Research International 2014;2014:951512. [DOI: 10.1155/2014/951512; PUBMED: 24511552] - DOI - PMC - PubMed
Jobe 2001
    1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2001; Vol. 163, issue 7:1723‐9. [DOI: 10.1164/ajrccm.163.7.2011060; PUBMED: 11401896] - DOI - PubMed
Krampera 2013
    1. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L, MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells ‐ The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013;15(9):1054‐61. [DOI: 10.1016/j.jcyt.2013.02.010; PUBMED: 23602578] - DOI - PubMed
Lalu 2012
    1. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta‐analysis of clinical trials. PLoS ONE 2012;7(10):e47559. [DOI: 10.1371/journal.pone.0047559; PUBMED: 23133515] - DOI - PMC - PubMed
Lapcharoensap 2015
    1. Lapcharoensap W, Gage SC, Kan P, Profit J, Shaw GM, Gould JB, et al. Hospital variation and risk factors for bronchopulmonary dysplasia in a population‐based cohort. JAMA Pediatrics 2015;169(2):e143676. [DOI: 10.1001/jamapediatrics.2014.3676; PUBMED: 25642906] - DOI - PubMed
Lughon 2011
    1. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. American Journal of Respiratory and Critical Care Medicine 2011;183(12):1715‐22. - PMC - PubMed
Marks 2017
    1. Marks PW, Witten CM, Califf RM. Clarifying stem‐cell therapy’s benefits and risks. New England Journal of Medicine 2017;376(11):1007‐9. - PubMed
Mendicino 2014
    1. Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC‐based product characterization for clinical trials: an FDA perspective. Cell Stem Cell 2014;14(2):141‐5. [DOI: 10.1016/j.stem.2014.01.013; PUBMED: 24506881] - DOI - PubMed
Murphy 2013
    1. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental & Molecular Medicine 2013;45:e54. [DOI: 10.1038/emm.2013.94; PUBMED: 24232253] - DOI - PMC - PubMed
NIH 1979
    1. National Institutes of Health. Report of workshop on bronchopulmonary dysplasia. Washington, DC: National Institutes of Health; 1979. NIH Publication No. 80‐1660.
Ning 2008
    1. Ning H, Yang F, Jiang M, Liangding H, Feng K, Zhang J, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008;22(3):593–9. - PubMed
Panchalingam 2015
    1. Panchalingam KM, Jung S, Rosenberg L, Behie LA. Bioprocessing strategies for the large‐scale production of human mesenchymal stem cells: a review. Stem Cell Research & Therapy 2015;6:225. [DOI: 10.1186/s13287-015-0228-5; PUBMED: 26597928] - DOI - PMC - PubMed
Papile 1978
    1. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics 1978;92(4):529‐34. [PUBMED: 305471] - PubMed
Pierro 2013
    1. Pierro M, Ionescu L, Montemurro T, Vadivel A, Weissmann G, Oudit G, et al. Short‐term, long‐term and paracrine effect of human umbilical cord‐derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013;68(5):475‐84. [DOI: 10.1136/thoraxjnl-2012-202323; PUBMED: 23212278] - DOI - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sammour 2016
    1. Sammour I, Somashekar S, Huang J, Batlahally S, Breton M, Valasaki K, et al. The effect of gender on mesenchymal stem cell (MSC) efficacy in neonatal hyperoxia‐induced lung injury. PLoS ONE 2016;11(10):e0164269. [DOI: 10.1371/journal.pone.0164269; PUBMED: 27711256] - DOI - PMC - PubMed
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, (editors). GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. www.guidelinedevelopment.org/handbook Updated October 2013 (accessed prior to 23 October 2017).
Sensebe 2011
    1. Sensebe L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Human Gene Therapy 2011;22(1):19–26. [DOI: 10.1089/hum.2010.197; PUBMED: 21028982] - DOI - PubMed
Shen 2015
    1. Shen SP, Liu WT, Lin Y, Li YT, Chang CH, Chang FW, et al. EphA2 is a biomarker of hMSCs derived from human placenta and umbilical cord. Taiwanese Journal of Obstetrics & Gynecology 2015;54(6):749‐56. [DOI: 10.1016/j.tjog.2015.10.012; PUBMED: 26700997] - DOI - PubMed
Shennan 1988
    1. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82(4):527–32. [PUBMED: 3174313] - PubMed
Song 2015
    1. Song K, Li W, Li M. Acute promyelocytic leukemia following autologous bone marrow‐derived mesenchymal stem cell transplantation for traumatic brain injury: a case report. Oncology Letters 2015;10(5):2905‐8. - PMC - PubMed
Speer 2006
    1. Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. Journal of Perinatology 2006;26(Suppl 1):S57‐62. [DOI: 10.1038/sj.jp.7211476; PUBMED: 16625227] - DOI - PubMed
Stoll 2010
    1. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126(3):443‐56. [DOI: 10.1542/peds.2009-2959; PUBMED: 20732945] - DOI - PMC - PubMed
Sullivan 2008
    1. Sullivan MJ. Banking on cord blood stem cells. Nature reviews. Cancer 2008;8(7):555‐63. [DOI: 10.1038/nrc2418; PUBMED: 18548085] - DOI - PubMed
van Haaften 2009
    1. Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. American Journal of Respiratory and Critical Care Medicine 2009;180(11):1131‐42. [DOI: 10.1164/rccm.200902-0179OC; PUBMED: 19713449] - DOI - PMC - PubMed
Wagner 2008
    1. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 2008;3(5):e2213. [DOI: 10.1371/journal.pone.0002213; PUBMED: 18493317] - DOI - PMC - PubMed
Walsh 2003
    1. Walsh MC, Wilson‐Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. Journal of Perinatology 2003;23(6):451–6. [DOI: 10.1038/sj.jp.7210963; PUBMED: 13679930] - DOI - PubMed
Walsh 2006
    1. Walsh MC, Szefler S, Davis J, Allen M, Marter L, Abman S, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 2006;117(3 Pt 2):S52‐6. [DOI: 10.1542/peds.2005-0620I; PUBMED: 16777823] - DOI - PubMed
Waszak 2012
    1. Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thébaud B. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen‐induced neonatal lung injury in rats. Stem Cells and Development 2012;21(15):2789‐97. [DOI: 10.1089/scd.2010.0566; PUBMED: 22533467] - DOI - PubMed
Watterberg 2010
    1. Watterberg KL, American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement ‐ postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010;126(4):800‐8. [DOI: 10.1542/peds.2010-1534; PUBMED: 20819899] - DOI - PubMed
Zhao 2017
    1. Zhao R, Su Z, Wu J, Ji HL. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta‐analysis. Oncotarget 2017;8(18):30511‐23. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources